Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab DOI Creative Commons

Maria L. Agostini,

Gretja Schnell,

Julia di Iulio

et al.

Future Virology, Journal Year: 2024, Volume and Issue: 19(5), P. 185 - 198

Published: March 23, 2024

Aim: Sotrovimab, an engineered human monoclonal antibody, targets a conserved region of the SARS-CoV-2 spike protein. The phase III COMET-TAIL study evaluated noninferiority intravenous versus intramuscular sotrovimab for early treatment high-risk COVID-19 in 973 participants. Materials & methods: We investigated prevalence variants concern/interest (VOC/VOI) and characterized baseline, postbaseline treatment-emergent epitope amino acid substitutions. Results: Delta variant was predominant; Alpha, or Mu were detected participants meeting primary clinical endpoint progression. Of 82 with substitutions, two baseline substitutions met Conclusion: Overall, there no evidence that specific VOC/VOI, impacted

Language: Английский

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants DOI Creative Commons
Daniele Focosi, Arturo Casadevall, Massimo Franchini

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(2), P. 217 - 217

Published: Jan. 31, 2024

Among the anti-Spike monoclonal antibodies (mAbs), S-309 derivative sotrovimab was most successful in having longest temporal window of clinical use, showing a high degree resiliency to SARS-CoV-2 evolution interrupted only by appearance BA.2.86* variant interest (VOI). This success undoubtedly reflects rational selection target highly conserved epitope coronavirus Spike proteins. We review here efficacy against different variants outpatients and inpatients, discussing both randomized controlled trials real-world evidence. Although it could not be anticipated at time its development introduction, sotrovimab's use immunocompromised individuals who harbor large populations viruses created conditions for eventual demise, as antibody viral led withdrawal due inefficacy later lineages. Despite this, based on observational data, some authorities have continued promote sotrovimab, but lack binding newer strongly argues futility use. The story highlights power modern biomedical science generate novel therapeutics while also providing cautionary tale need devise strategies minimize emergence resistance antibody-based therapeutics.

Language: Английский

Citations

20
Monitoring the Emergence of Resistance With Sotrovimab in Immunocompromised Patients With COVID-19: LUNAR Study DOI Creative Commons
Judith Breuer, Myriam Gharbi,

Jill Walker

et al.

Journal of Infection, Journal Year: 2025, Volume and Issue: unknown, P. 106510 - 106510

Published: May 1, 2025

Language: Английский

Citations

0
Post COVID-19 Reflections and Questions: How Prepared Are We for the Next Pandemic? DOI Open Access
George J. Kontoghiorghes,

Annita Kolnagou,

Christina Kontoghiorghe

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(2), P. 859 - 859

Published: Jan. 10, 2024

While the end of COVID-19 pandemic was announced earlier in 2023 by WHO, currently dominating virus variants, such as omicron sub-lineages XBB [...]

Language: Английский

Citations

1
Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab DOI Creative Commons

Maria L. Agostini,

Gretja Schnell,

Julia di Iulio

et al.

Future Virology, Journal Year: 2024, Volume and Issue: 19(5), P. 185 - 198

Published: March 23, 2024

Aim: Sotrovimab, an engineered human monoclonal antibody, targets a conserved region of the SARS-CoV-2 spike protein. The phase III COMET-TAIL study evaluated noninferiority intravenous versus intramuscular sotrovimab for early treatment high-risk COVID-19 in 973 participants. Materials & methods: We investigated prevalence variants concern/interest (VOC/VOI) and characterized baseline, postbaseline treatment-emergent epitope amino acid substitutions. Results: Delta variant was predominant; Alpha, or Mu were detected participants meeting primary clinical endpoint progression. Of 82 with substitutions, two baseline substitutions met Conclusion: Overall, there no evidence that specific VOC/VOI, impacted

Language: Английский

Citations

0